© 2020 MJH Life Sciences and OncLive. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2020 MJH Life Sciences™ and OncLive. All rights reserved.
September 16, 2020
Thomas G. Martin, MD, discusses the importance of targeted therapy in multiple myeloma, in addition to ongoing research.
Jeffrey Wolf, MD, discusses how induction therapies continue to improve the depth of response in patients with multiple myeloma and how it may be possible to eliminate the need for autologous stem cell transplant in this population.
September 15, 2020
The combination of tremelimumab and durvalumab improved overall response rate and median overall survival in patients with unresectable hepatocellular carcinoma previously treated with sorafenib.
September 11, 2020
Shagun Arora, MD, discusses the rapidly advancing multiple myeloma treatment landscape.
September 10, 2020
Sandy Wong, MD, highlights recent developments in light chain amyloidosis.
September 03, 2020
Nina Shah, MD, discusses the phase 1/2 EVOLVE study with orvacabtagene autoleucel in relapsed/refractory multiple myeloma.